Last 12 months
Inside the activity.
2 purchase rows · 30 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2021 Filed May 5, 2021 21:35 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 300 | $384.91 | $115,473.00 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,053 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 500 | $382.48 | $191,240.00 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,353 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 126 | $378.99 | $47,752.74 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,853 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 248 | $377.97 | $93,736.81 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,979 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F5 · price: This transaction was executed in multiple trades at prices ranging from $377.85 to $378.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 487 | $376.98 | $183,590.14 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,227 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F4 · price: This transaction was executed in multiple trades at prices ranging from $376.850 to $377.374. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:35 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 2,543 | $376.33 | $957,014.31 |
DisclosureSEC source: 0001093557-21-000128 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,714 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F2 · price: This transaction was executed in multiple trades at prices ranging from $375.80 to $376.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 22:27 UTC |
Murphy Patrick MichaelEVP, Chief Legal Officer
|
SaleCommon Stock | 500 | $415.83 | $207,915.00 |
DisclosureSEC source: 0001093557-21-000121 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,241 F1 · shares: On August 28, 2020, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 00:09 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 347 | $411.32 | $142,727.10 |
DisclosureSEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,400 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $411.21 to $411.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 00:09 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 436 | $410.69 | $179,058.97 |
DisclosureSEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,747 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $409.965 to $410.820. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 00:09 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 296 | $408.58 | $120,941.07 |
DisclosureSEC source: 0001093557-21-000117 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,183 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $408.55 to $408.64. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:44 UTC |
Flynn Paul REVP, Global Revenue
|
SaleCommon Stock | 758 | $400.00 | $303,200.00 |
DisclosureSEC source: 0001093557-21-000115 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP, Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,306 F1 · shares: On December 11, 2020, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 12,306 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:05 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 1,179 | $367.41 | $433,176.98 |
DisclosureSEC source: 0001093557-21-000107 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,257 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F5 · price: This transaction was executed in multiple trades at prices ranging from $367.17 to $367.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:05 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 3,567 | $366.84 | $1,308,535.76 |
DisclosureSEC source: 0001093557-21-000107 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,436 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F4 · price: This transaction was executed in multiple trades at prices ranging from $366.176 to $367.165. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:05 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 1,475 | $365.67 | $539,369.15 |
DisclosureSEC source: 0001093557-21-000107 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,003 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F2 · price: This transaction was executed in multiple trades at prices ranging from $365.120 to $366.108. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:45 UTC |
Murphy Patrick MichaelEVP, Chief Legal Officer
|
SaleCommon Stock | 500 | $350.00 | $175,000.00 |
DisclosureSEC source: 0001093557-21-000099 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,741 F1 · shares: On August 28, 2020, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 166 | $362.30 | $60,141.42 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,479 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $362.13 to $362.45. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 229 | $360.90 | $82,645.66 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,645 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $360.805 to $361.590. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 589 | $360.36 | $212,252.51 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,874 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $359.69 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 77 | $358.13 | $27,576.01 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,463 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 18 | $352.88 | $6,351.84 |
DisclosureSEC source: 0001093557-21-000093 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,540 F1 · shares: On June 15, 2020, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
DOUBLEDAY RICHARDEVP Chief Commercial Officer
|
SaleCommon Stock | 94 | $362.45 | $34,070.30 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,654 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
DOUBLEDAY RICHARDEVP Chief Commercial Officer
|
SaleCommon Stock | 268 | $361.37 | $96,846.70 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,748 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
DOUBLEDAY RICHARDEVP Chief Commercial Officer
|
SaleCommon Stock | 655 | $360.33 | $236,017.66 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,016 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
DOUBLEDAY RICHARDEVP Chief Commercial Officer
|
SaleCommon Stock | 74 | $358.13 | $26,501.62 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,671 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC |
DOUBLEDAY RICHARDEVP Chief Commercial Officer
|
SaleCommon Stock | 18 | $352.88 | $6,351.84 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,745 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 18, 2021 Filed May 25, 2021 23:15 UTC |
AUGUSTINOS NICHOLASDirector
|
OtherCommon Stock | 2,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000135 · edgardoc.xml · nonDerivative · entry 3 AUGUSTINOS NICHOLAS · CIK 0001238485 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,900 F1 · shares: Shares were transferred from ownership under the Kirschner/Augustinos Revocable Trust to direct ownership. F5 · balance_after: Shares are held by the Kirschner/Augustinos Revocable Trust, of which the reporting person is trustee. Read SEC document |
| March 18, 2021 Filed May 25, 2021 23:15 UTC |
AUGUSTINOS NICHOLASDirector
|
OtherCommon Stock | 2,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000135 · edgardoc.xml · nonDerivative · entry 1 AUGUSTINOS NICHOLAS · CIK 0001238485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,998 F1 · shares: Shares were transferred from ownership under the Kirschner/Augustinos Revocable Trust to direct ownership. F2 · balance_after: Included in this number are 806 restricted stock units which were granted on May 22, 2020 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2021 Annual Meeting. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:41 UTC |
Selvaraj Shelly RamasamySVP Information Technology
|
SaleCommon Stock | 1,867 | $355.86 | $664,390.62 |
DisclosureSEC source: 0001093557-21-000078 · edgardoc.xml · nonDerivative · entry 2 Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,136 F3 · shares: On May 30, 2019, Mr. Selvaraj adopted a 10b5-1 Plan which was amended on May 11, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Selvaraj. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:42 UTC |
Sylvain Jereme MSVP, Finance & CAO
|
SaleCommon Stock | 941 | $362.92 | $341,504.90 |
DisclosureSEC source: 0001093557-21-000079 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,108 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:41 UTC |
Selvaraj Shelly RamasamySVP Information Technology
|
SaleCommon Stock | 2,700 | $362.92 | $979,875.90 |
DisclosureSEC source: 0001093557-21-000078 · edgardoc.xml · nonDerivative · entry 1 Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,003 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:40 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 14,044 | $362.92 | $5,096,806.35 |
DisclosureSEC source: 0001093557-21-000077 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,478 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:40 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 5,566 | $362.92 | $2,019,996.02 |
DisclosureSEC source: 0001093557-21-000076 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,558 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:39 UTC |
Murphy Patrick MichaelEVP, Chief Legal Officer
|
SaleCommon Stock | 3,471 | $362.92 | $1,259,684.91 |
DisclosureSEC source: 0001093557-21-000075 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,241 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 15,413 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 3,905 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:38 UTC |
Leach Jacob StevenEVP Chief Technology Officer
|
SaleCommon Stock | 5,353 | $362.92 | $1,942,694.70 |
DisclosureSEC source: 0001093557-21-000074 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,396 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:38 UTC |
Blackford Quentin S.Chief Operating Officer & CFO
|
SaleCommon Stock | 6,509 | $362.22 | $2,357,688.03 |
DisclosureSEC source: 0001093557-21-000073 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Chief Operating Officer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,165 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 37,709 unvested restricted stock units, 7,491 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 6,144 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 15,590 of which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:37 UTC | SaleCommon Stock | 5,566 | $362.92 | $2,019,996.02 |
DisclosureSEC source: 0001093557-21-000072 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · * 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,307 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,171 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
|
| March 10, 2021 Filed Mar 12, 2021 22:36 UTC |
Abbey DonaldEVP Quality and Regulatory Aff
|
SaleCommon Stock | 5,566 | $362.92 | $2,019,996.02 |
DisclosureSEC source: 0001093557-21-000071 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,937 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 16,171 restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
Selvaraj Shelly RamasamySVP Information Technology
|
SaleCommon Stock | 152 | $356.94 | $54,254.88 |
DisclosureSEC source: 0001093557-21-000056 · edgardoc.xml · nonDerivative · entry 2 Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,703 F3 · shares: On May 30, 2019, Mr. Selvaraj adopted a 10b5-1 Plan which was amended on May 11, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Selvaraj. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 200 | $364.33 | $72,866.00 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,522 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F11 · price: This transaction was executed in multiple trades at prices ranging from $364.00 to $364.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 574 | $362.87 | $208,289.73 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,722 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F10 · price: This transaction was executed in multiple trades at prices ranging from $362.58 to $363.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 1,127 | $362.29 | $408,304.21 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,296 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F9 · price: This transaction was executed in multiple trades at prices ranging from $361.58 to $362.55. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 700 | $361.02 | $252,711.41 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,423 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F8 · price: This transaction was executed in multiple trades at prices ranging from $360.44 to $361.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 550 | $359.82 | $197,902.49 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,123 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F7 · price: This transaction was executed in multiple trades at prices ranging from $359.44 to $360.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 400 | $358.75 | $143,498.52 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,673 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F6 · price: This transaction was executed in multiple trades at prices ranging from $358.40 to $359.35. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 306 | $356.94 | $109,223.64 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,073 F5 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 31, 2020, and amended effective December 16, 2020. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:30 UTC |
Sylvain Jereme MSVP, Finance & CAO
|
GrantCommon Stock | 5,301 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-21-000058 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,049 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 11,837 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 1,608 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 1,274 of which were granted on November 8, 2018 and shall vest through November 8, 2021. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:23 UTC |
Leach Jacob StevenEVP Chief Technology Officer
|
GrantCommon Stock | 7,171 | $0.00 | $7.17 |
DisclosureSEC source: 0001093557-21-000061 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,749 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 19,999 unvested restricted stock units, 7,171 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 4,996 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:29 UTC |
Stern SadieEVP Chief Human Resources Off
|
GrantCommon Stock | 5,634 | $0.00 | $5.63 |
DisclosureSEC source: 0001093557-21-000057 · edgardoc.xml · nonDerivative · entry 1 Stern Sadie · CIK 0001797971 · EVP Chief Human Resources Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,841 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 13,841 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 8,207 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:29 UTC |
Selvaraj Shelly RamasamySVP Information Technology
|
GrantCommon Stock | 3,073 | $0.00 | $3.07 |
DisclosureSEC source: 0001093557-21-000056 · edgardoc.xml · nonDerivative · entry 1 Selvaraj Shelly Ramasamy · CIK 0001805707 · SVP Information Technology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 9,484 unvested restricted stock units, 3,073 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,655 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
GrantCommon Stock | 13,445 | $0.00 | $13.45 |
DisclosureSEC source: 0001093557-21-000055 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,379 F3 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F4 · balance_after: Included in this number are 42,356 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 11,943 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.